 | |||||
| today deals | |||||
| NEWS | |||||
| Takeda signs off on a $2B deal aimed at bypassing AAV roadblocks on the way to gene therapy 2.0 The spotlight today falls on Code Biotherapeutics, a private startup run by ex-GSK BD chief Brian McVeigh. Endpoints News. Keep reading Endpoints with ...
| |||||
| See more results | Edit this alert | |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment